Merck & Company (MRK) Stock Forecast & Price Target

Compare

13,786 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MRK Analyst Ratings

Moderate Buy

10 Buy

7 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Merck

& Company

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MRK Stock 12 Month Forecast

Average Price Target

$103.80

▲(24.06%Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is $103.80 with a high forecast of $141.00 and a low forecast of $82.00. The average price target represents a 24.06% change from the last price of $83.67.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"74":"$74","91":"$91","108":"$108","125":"$125","142":"$142"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":141,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$141.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$103.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$82.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[74,91,108,125,142],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.81,86.36307692307693,90.91615384615385,95.46923076923078,100.02230769230769,104.57538461538462,109.12846153846155,113.68153846153847,118.23461538461538,122.78769230769231,127.34076923076924,131.89384615384614,136.4469230769231,{"y":141,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.81,83.50153846153846,85.19307692307693,86.88461538461539,88.57615384615384,90.2676923076923,91.95923076923077,93.65076923076923,95.34230769230768,97.03384615384616,98.72538461538461,100.41692307692307,102.10846153846154,{"y":103.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.81,81.82461538461538,81.83923076923077,81.85384615384615,81.86846153846155,81.88307692307693,81.89769230769231,81.91230769230769,81.92692307692307,81.94153846153846,81.95615384615385,81.97076923076924,81.98538461538462,{"y":82,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":123.72,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.58,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.74,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.98,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.81,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$141.00

Average Price Target$103.80

Lowest Price Target$82.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$94

Buy

12.35%

Upside

Reiterated

07/02/25

Merck & Company's stock score is driven by strong financial performance and attractive valuation metrics. The positive outlook from their earnings call and technical indicators suggest potential growth, although there are challenges such as declining sales in China and tariff impacts. The company's strategic focus on high-growth areas and a robust pipeline supports its long-term potential.

Vamil DivanGuggenheim

Guggenheim

$108

Buy

29.08%

Upside

Reiterated

07/13/25

Guggenheim Sticks to Its Buy Rating for Merck & Company (MRK)

Trung HuynhUBS

UBS

$105

Buy

25.49%

Upside

Reiterated

07/10/25

UBS Sticks to Their Buy Rating for Merck & Company (MRK)

Tycho PetersonJefferies

Jefferies

$138→$141

Buy

68.52%

Upside

Reiterated

07/10/25

Jefferies Sticks to Its Buy Rating for Merck & Company (MRK)

Terence FlynnMorgan Stanley

Morgan Stanley

$99→$98

Hold

17.13%

Upside

Reiterated

07/10/25

Merck & Company's Strategic Acquisition of Verona Pharma: Balancing Long-Term Gains with Short-Term Financial Adjustments

Tim AndersonBank of America Securities

Bank of America Securities

$99

Buy

18.32%

Upside

Reiterated

07/09/25

Merck's Strategic Acquisition of Verona Pharma: Enhancing Respiratory Portfolio Amidst Keytruda Competition

Evan SeigermanBMO Capital

BMO Capital

$82

Hold

-2.00%

Downside

Reiterated

07/09/25

BMO Capital Remains a Hold on Merck & Company (MRK)

Mohit BansalWells Fargo

Wells Fargo

$97

Hold

15.93%

Upside

Reiterated

07/09/25

Cautious Outlook on Merck & Company Amid International Sales Challenges for Gardasil and Keytruda

Carter GouldCantor Fitzgerald

Cantor Fitzgerald

$85→$83

Hold

-0.80%

Downside

Reiterated

07/09/25

Cantor Fitzgerald Remains a Hold on Merck & Company (MRK)

Asad HaiderGoldman Sachs

Goldman Sachs

$99

Buy

18.32%

Upside

Reiterated

07/09/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Courtney BreenBernstein

Bernstein

―

Hold

―

Reiterated

07/08/25

Merck & Company (MRK) Gets a Hold from Bernstein

Chris SchottJ.P. Morgan

J.P. Morgan

$130

Buy

55.37%

Upside

Reiterated

07/07/25

Merck & Company: Strong Growth Potential and Favorable Risk/Return Profile Amidst Keytruda's Performance and Diverse Portfolio

Luisa HectorBerenberg Bank

Berenberg Bank

$100

Buy

19.52%

Upside

Reiterated

07/01/25

Berenberg Bank Reaffirms Their Buy Rating on Merck & Company (MRK)

Steve ScalaTD Cowen

TD Cowen

$100

Hold

19.52%

Upside

Reiterated

06/26/25

TD Cowen Sticks to Their Hold Rating for Merck & Company (MRK)

Geoff MeachamCiti

Citi

―

Hold

―

Reiterated

06/24/25

Citi Keeps Their Hold Rating on Merck & Company (MRK)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$94

Buy

12.35%

Upside

Reiterated

07/02/25

Vamil DivanGuggenheim

Guggenheim

$108

Buy

29.08%

Upside

Reiterated

07/13/25

Guggenheim Sticks to Its Buy Rating for Merck & Company (MRK)

Trung HuynhUBS

UBS

$105

Buy

25.49%

Upside

Reiterated

07/10/25

UBS Sticks to Their Buy Rating for Merck & Company (MRK)

Tycho PetersonJefferies

Jefferies

$138→$141

Buy

68.52%

Upside

Reiterated

07/10/25

Jefferies Sticks to Its Buy Rating for Merck & Company (MRK)

Terence FlynnMorgan Stanley

Morgan Stanley

$99→$98

Hold

17.13%

Upside

Reiterated

07/10/25

Merck & Company's Strategic Acquisition of Verona Pharma: Balancing Long-Term Gains with Short-Term Financial Adjustments

Tim AndersonBank of America Securities

Bank of America Securities

$99

Buy

18.32%

Upside

Reiterated

07/09/25

Merck's Strategic Acquisition of Verona Pharma: Enhancing Respiratory Portfolio Amidst Keytruda Competition

Evan SeigermanBMO Capital

BMO Capital

$82

Hold

-2.00%

Downside

Reiterated

07/09/25

BMO Capital Remains a Hold on Merck & Company (MRK)

Mohit BansalWells Fargo

Wells Fargo

$97

Hold

15.93%

Upside

Reiterated

07/09/25

Cautious Outlook on Merck & Company Amid International Sales Challenges for Gardasil and Keytruda

Carter GouldCantor Fitzgerald

Cantor Fitzgerald

$85→$83

Hold

-0.80%

Downside

Reiterated

07/09/25

Cantor Fitzgerald Remains a Hold on Merck & Company (MRK)

Asad HaiderGoldman Sachs

Goldman Sachs

$99

Buy

18.32%

Upside

Reiterated

07/09/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Courtney BreenBernstein

Bernstein

―

Hold

―

Reiterated

07/08/25

Merck & Company (MRK) Gets a Hold from Bernstein

Chris SchottJ.P. Morgan

J.P. Morgan

$130

Buy

55.37%

Upside

Reiterated

07/07/25

Merck & Company: Strong Growth Potential and Favorable Risk/Return Profile Amidst Keytruda's Performance and Diverse Portfolio

Luisa HectorBerenberg Bank

Berenberg Bank

$100

Buy

19.52%

Upside

Reiterated

07/01/25

Berenberg Bank Reaffirms Their Buy Rating on Merck & Company (MRK)

Steve ScalaTD Cowen

TD Cowen

$100

Hold

19.52%

Upside

Reiterated

06/26/25

TD Cowen Sticks to Their Hold Rating for Merck & Company (MRK)

Geoff MeachamCiti

Citi

―

Hold

―

Reiterated

06/24/25

Citi Keeps Their Hold Rating on Merck & Company (MRK)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

1 Month

xxx

Success Rate

10/14 ratings generated profit

Average Return

+1.76%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +1.76% per trade.

3 Months

xxx

Success Rate

9/14 ratings generated profit

Average Return

+2.45%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +2.45% per trade.

1 Year

Tim AndersonBank of America Securities

Success Rate

8/14 ratings generated profit

Average Return

+3.63%

reiterated a buy rating 7 days ago

Copying Tim Anderson's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +3.63% per trade.

2 Years

xxx

Success Rate

13/17 ratings generated profit

Average Return

+12.44%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 76.47% of your transactions generating a profit, with an average return of +12.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRK Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MRK has received 17 Buy Ratings, 21 Hold Ratings, and 1 Sell Ratings. MRK average Analyst price target in the past 3 months is 103.80.

Each month's total comprises the sum of three months' worth of ratings.

MRK Financial Forecast

MRK Earnings Forecast

Next quarter’s earnings estimate for MRK is $2.03 with a range of $1.88 to $2.13. The previous quarter’s EPS was $2.22. MRK beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.45% of the time in the same period. In the last calendar year MRK has Preformed in-line its overall industry.

MRK Sales Forecast

Next quarter’s sales forecast for MRK is $15.86B with a range of $15.57B to $16.81B. The previous quarter’s sales results were $15.62B. MRK beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 57.81% of the time in the same period. In the last calendar year MRK has Preformed in-line its overall industry.

MRK Stock Forecast FAQ

What is MRK’s average 12-month price target, according to analysts?

Based on analyst ratings, Merck & Company’s 12-month average price target is 103.80.

What is MRK’s upside potential, based on the analysts’ average price target?

Merck & Company has 24.06% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MRK a Buy, Sell or Hold?

Merck & Company has a consensus rating of Moderate Buy which is based on 10 buy ratings, 7 hold ratings and 0 sell ratings.

What is Merck & Company’s price target?

The average price target for Merck & Company is 103.80. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $141.00 ,the lowest forecast is $82.00. The average price target represents 24.06% Increase from the current price of $83.67.

What do analysts say about Merck & Company?

Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of MRK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Merck & Company (MRK) Stock Forecast & Price Target

MRK Analyst Ratings

MRK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Merck & Company

MRK Analyst Recommendation Trends

MRK Financial Forecast

MRK Earnings Forecast

MRK Sales Forecast

MRK Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts